Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 10 February 2016 | By Zachary Brennan
As Congress continues to push for the US Food and Drug Administration (FDA) to speed the approval of new generic drugs, which could be key for keeping pharmaceutical prices in check, FDA for the first time is offering an in-depth look at where it stands with industry’s abbreviated new drug applications (ANDAs).
What’s clear from the new data on 2015 is that FDA continues to seek more information or require companies to correct what’s known as an “easily correctible deficiency” for the vast majority of ANDAs. And in case the ANDA approval process seems to be nothing more than a formality, the statistics show that FDA is actually rejecting far more ANDAs than it’s approving. In fact, for one-third of 2015, or four months, FDA rejected more than twice as many ANDAs as it approved.
FDA prioritizes the review of ANDAs for “first generics,” which offer the first round of market competition for brand name drugs as patent and exclusivity barriers to approval have been lifted or will be lifted soon. FDA also prioritizes ANDAs for which the product is in shortage, is subject to special review programs like the President’s Emergency Plan for AIDS Relief (PEPFAR), is related to public health emergencies and certain government purchasing programs, or is subject to statutory or other legal requirements.
Some in Congress are now pushing for FDA to also prioritize ANDAs for products seeing steep price increases, though that could be difficult for the agency, as it currently does not track drug prices.
As far as where FDA stands with its backlog of ANDA applications, 2,962 ANDAs are currently with FDA (as of January 2016), though 2,170 have received at least one communication from the agency staff and only 211 are pending review.
On industry’s end, 1,143 have been sent back to generic drug companies and are either pending a response from industry or have received tentative approval. FDA ended last year at a new monthly high of 99 approvals and tentative approvals in December.
The dashboard was released little more than a week after Janet Woodcock, director of the Center for Drug Evaluation and Research, told senators that the agency expects to be fully caught up with the backlog before the re-authorization of the next Generic Drug User Fee Act (GDUFA) in 2017.
Woodcock made clear that the long median times for ANDA approvals, cited often by senators, actually include ANDAs that have technically been backlogged since GDUFA began.
This year, it will take FDA about 15 months to respond to a generic firm on their ANDA, and in October 2016, companies can expect to get a response within 10 months, Woodcock said.
FDA and industry discussions on GDUFA II, which began in October, have recently focused on the ANDA review timeframe and review goal metrics, particularly around transparency, pre-ANDA processes, controlled correspondence, first generics and regulatory science.
FDA and industry also have discussed the current FDA facility evaluation model and drug master file scientific review and completeness assessments. Both sides have agreed that they are generally aligned on major principles for GDUFA II, according to minutes from a meeting in January.
Generic Drug Review Dashboard
Tags: generic drug review, ANDA backlog, FDA and ANDAs, generic drug applications
Regulatory Focus newsletters
All the biggest regulatory news and happenings.